According to latest report, the global genome editing market size was USD 8.45 billion in 2023, calculated at USD 9.88 billion in 2024, and is expected to reach around USD 40.48 billion by 2033, expanding at a CAGR of 16.96% from 2024 to 2033, North America dominated the market with the largest revenue share of 49% in 2023.
Get Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/7129
Gene editing technologies, such as CRISPR-Cas9, TALENs, ZFNs, and meganucleases, represent pivotal advancements enabling scientists to enhance the characteristics of organisms ranging from plants to animals and bacteria. These technologies function akin to molecular scissors, precisely cutting DNA at targeted locations and facilitating the removal, addition, or replacement of specific DNA sequences. By altering DNA, scientists can modify physical traits like eye color and mitigate disease risks, thereby expanding the applications of genome editing across various sectors. The continuous development and application of these technologies are pivotal in driving growth within the genome editing market, fostering innovation and broader adoption across scientific and industrial domains.
Genome editing using clustered regularly interspaced short palindromic repeats (CRISPR) has revolutionized the ability to precisely and efficiently modify DNA within cells. This technique involves the Cas9 protein, guided by RNA, targeting specific DNA sequences and inducing cuts at precise locations marked by protospacer adjacent motif (PAM) sequences. These cuts enable scientists to disable or alter DNA sequences, facilitating precise modifications such as edits to genetic sequences or adding/removing sections of DNA.
Genome editing holds immense potential to transform cellular and organismal characteristics, offering applications across various fields including agriculture, medicine, and biotechnology. The continuous advancement and adoption of CRISPR-based technologies are key drivers propelling rapid growth within the genome editing market, fueling innovation and expanding possibilities for genetic manipulation and therapeutic applications.
Key Takeaways:
- North America dominated the market and accounted for a 49% share in 2023
- Asia Pacific is anticipated to witness the fastest growth at a CAGR of 18.75% from 2024 to 2033
- The CRISPR/Cas9 segment held the largest market share of 43.89% of the global revenue in 2023.
- The ZFN segment is expected to witness a substantial CAGR of 16.56% over the forecast period.
- The ex-vivo segment dominated the market with a share of 51.65% in 2023.
- The in-vivo segment is projected to witness the fastest growth at a CAGR of 19.94% from 2024 to 2033
- The genetic engineering segment held the largest market share in 2023
- The clinical applications segment is expected to grow at a significant CAGR of 13.19% over the forecast period.
- The contract segment dominated the market in 2023
- The in-house segment is expected to witness lucrative growth over the forecast period
- The biotechnology and pharmaceutical companies segment accounted for the largest market share of 52% in 2023.
- The academic and research institutions segment is expected to grow at the fastest CAGR of 19.22% over the forecast period.
Immediate Delivery Available, Get Full Access@ https://www.novaoneadvisor.com/report/checkout/7129
U.S. Genome Editing Market Size and Growth
The U.S. genome editing market size was valued at USD 4.14 billion in 2024 and is projected to surpass around USD 16.49 billion by 2033, registering a CAGR of 16.6% over the forecast period of 2024 to 2033.
North America has emerged as a dominant force in the genome editing market, driven by strong public support and significant scientific advancements in CRISPR technology. Americans are increasingly receptive to gene editing techniques for therapeutic applications, particularly in treating heritable blood disorders like sickle cell anemia, as evidenced by promising clinical trial outcomes. This optimism, public opinion reflects a nuanced perspective on the ethical implications of gene editing for disease prevention in babies. A majority believes that widespread adoption of gene editing could lead to societal pressures for parents to utilize these technologies to mitigate disease risks in offspring. This regional landscape underscores North America's pivotal role in shaping the future of genome editing through technological innovation and evolving public discourse on ethical considerations.
- In September 2023, Regeneron Pharmaceuticals, Inc. completed its acquisition of Decibel Therapeutics, enhancing its gene therapy and auditory programs
Asia Pacific is anticipated to witness the fastest growth at a CAGR of 18.75% from 2024 to 2033, driven by significant opportunities in crop improvement and agricultural innovation. With more than half of the world's population residing in the region, there is a pressing need for sustainable agricultural practices to ensure food security. Genome editing technologies offer a promising solution by enabling precise modifications to crop genomes, enhancing traits such as yield, disease resistance, and nutritional content. Countries in Asia Pacific, including India, are keenly adopting genome editing to tailor agricultural products to meet specific demands.
Institutions like the National Agri-Food Biotechnology Institute (NABI) are pioneering efforts in applying genome editing tools to a wide range of crops such as banana, rice, wheat, tomato, and millet. This proactive approach positions Asia Pacific as a hub for innovation in agricultural biotechnology, fostering partnerships and research collaborations aimed at harnessing the full potential of genome editing to address regional food challenges and promote sustainable agriculture.
U.S. Genome Editing Market Trends
The presence of robust research infrastructure, a rise in genetically modified crops, and an increase in the prevalence of genetic diseases are some of the major factors boosting the U.S. genome editing market’s growth. Moreover, in the U.S., genetic diseases such as cystic fibrosis are prevalent. On the other hand, a rise in the number of patent approvals for U.S.-based companies has also accelerated the adoption of genome editing tools in the country, leading to positive market growth. Further, with increased government funding and support for scientific R&D, the U.S. held the largest market share for genome editing technology in North America.
Europe Genome Editing Market Trends
The genome editing market in Europe was identified as lucrative. This is attributed to the adoption of new rules related to genome editing by European countries creating an opportunity for the market.
The UK genome editing market presents several potential opportunities that favor an increase in the usage of advanced genome editing tools. Numerous efforts undertaken by UK-based genome editing companies and funding initiatives supported by private & public entities drive the UK market’s growth. In September 2021, the UK’S Department for Environment, Food and Rural Affairs (Defra) declared that by the end of 2021, researchers who wanted to conduct field trials of gene-edited plants will no longer be required to submit risk assessments.
The genome editing market in France growth is driven by the rising prevalence of hereditary diseases, such as hemophilia and metabolic disorders. To cure such disorders, several researchers are using genome editing technologies. Furthermore, France is undertaking several efforts to drive innovation in plant genetics, thereby boosting market growth in the country. Some of the 28 leading private and public research organizations involved in plant breeding, plant science, and connected technologies formed the Plant Alliance.
The Germany genome editing market generated significant revenue in Europe in 2023, which can be attributed to the presence of developed global companies, such as Merck KGaA & QIAGEN, which offer genome editing and related products. The collaboration and partnership models among key players strengthen their market presence in the country as well as at a global level, hence, driving the revenue in the country.
Asia Pacific Genome Editing Market Trends
Asia Pacific is anticipated to witness the fastest growth at a CAGR of 18.75% from 2024 to 2033. The regional market growth is expected to be driven by the increasing demand for gene editing technologies and the rising prevalence of genetic disorders and diseases across countries like India and Australia. Moreover, the domestic companies providing gene editing products and services are attracting investments and funding. For instance, in April 2021, GenScript launched Research-Grade Lentiviral Vector Packaging Service for drug discovery, cell line development, and gene editing.
The China genome editing market is growth is driven by the local presence of key market players, such as GenScript. The company is taking initiatives to promote genome engineering services such as CRISPR services and gene services. The China market for genome editing is ready for growth due to the Chinese government's increasing focus on precision medicine and the presence of major players such as BGI, and Hebei Senlang Biotechnology.
The genome editing market in Japan is characterized by an increasing number of Japanese companies that are acquiring licenses to the CRISPR-Cas9 technology, potentially driving market growth. In addition, an increasing prevalence of genetic diseases and diabetics coupled with growing genomic research initiatives is expected to drive the market in Japan. In Japan, around 13.5% of the total population either has type 2 diabetes or impaired glucose tolerance.
The India genome editing market is expected grow in the near future. India possesses a high growth potential due to the high competency and intense demand for genome editing technology to improve agriculture productivity suitably. In the country, the Department of Biotechnology’s (DBT) National Agri-Food Biotechnology Institute is utilizing CRISPR genome editing technology to modify bananas. Moreover, ongoing research projects related to CRISPR/Cas9 by Indian researchers and scientists are expected to drive the market growth.
Middle East And Africa Genome Editing Market Trends
The genome editing market in Middle East and Africa is projected to grow in the forthcoming years. The increasing applications of biotechnology in healthcare are contributing to the expansion of the market in this region.
The Saudi Arabia genome editing market is characterized by several ongoing research projects related to CRISPR genome editing technology which are expected to boost the market growth over the forecast period. The rising adoption of CRISPR technology for enhancing the immune system of plants is expected to drive market growth in the coming years.
The genome editing market in Kuwait is expected to witness rapid growth in the coming decade due to the increasing investment in scientific R&D, both by the government and private sector, which drives innovation in genetic technologies. This investment creates opportunities to develop new and improved genome editing tools and techniques.
Immediate Delivery Available, Get Full Access@ https://www.novaoneadvisor.com/report/checkout/7129
Market Dynamics
Driver
Versatile Genome-Editing Technologies
The emergence of highly versatile genome-editing technologies, such as CRISPR-Cas9, TALENs, ZFNs, and engineered Cas9 nickases, has revolutionized the ability to make precise, sequence-specific modifications in a wide range of cell types and organisms economically and swiftly. Recent advancements, including single-base editing without DNA breaks and self-inactivating vectors that link genomic modifications to self-degradation, promise enhanced specificity in editing. This potential reduction in off-target effects is critical as it correlates with the duration of cellular exposure to nucleases. These innovations are poised to fuel growth in the genome editing market by addressing key challenges and expanding therapeutic applications in clinically relevant settings.
Restraint
Challenges in Long-term Expression of Genome Editing Tools
Genome editing tools ideally require transient expression in target cells to mitigate risks of off-target nuclease genotoxicity and immune responses to prokaryotic proteins. Advancements and hundreds of therapies in clinical trials, the high costs associated with these treatments, often around US$1 million per procedure plus additional expenses for hospitalization and procedural complexities, pose significant barriers. These financial implications limit broader adoption and growth of the genome editing market, necessitating innovations to streamline costs and enhance accessibility for wider patient populations.
Opportunity
Advancements in HDR-Mediated Gene Editing
Precise genome editing, crucial for both preclinical research and clinical gene therapy, has traditionally relied on HDR (homology-directed repair). Recent efforts to enhance HDR efficiency include using rationally designed single-stranded oligodeoxynucleotide (ssODN) templates and employing NHEJ (non-homologous end joining) inhibitors. The delivery of Cas9 and HDR templates via AAVs has successfully achieved precise genome editing in post-mitotic neurons and cardiomyocytes. These advancements, HDR-mediated editing efficiency remains lower compared to the more predominant NHEJ pathway, which can introduce unintended genomic alterations. Addressing these challenges presents significant opportunities for innovation and growth within the genome editing market, particularly in enhancing HDR-mediated techniques and minimizing off-target effects.
Immediate Delivery Available, Get Full Access@ https://www.novaoneadvisor.com/report/checkout/7129
Report Highlights
By Technology Insights
The CRISPR/Cas9 segment held the largest market share of 43.89% of the global revenue in 2023, holding the largest market share due to its remarkable efficiency, precision, and versatility across various disciplines. Adapted from bacteria's natural immune defense mechanism against viruses, CRISPR/Cas9 enables precise modifications to DNA by using guide RNA (gRNA) to target specific genetic sequences. The Cas9 enzyme then cleaves the DNA at the targeted site, initiating the repair process that allows for editing genetic material in living cells. This revolutionary technology operates through a streamlined process of recognition, cleavage, and repair, offering researchers unprecedented capabilities to edit genes in a wide array of organisms and applications. Its adaptability has spurred innovation in agriculture, medicine, biotechnology, and beyond, making CRISPR/Cas9 a pivotal tool for advancing scientific research and addressing complex genetic challenges. As research continues to refine and expand the applications of CRISPR/Cas9, it remains at the forefront of genome editing technologies, driving significant developments and market growth worldwide.
The ZFN segment is expected to witness a substantial CAGR of 16.56% over the forecast period, driven by their role as precise gene-targeting tools. ZFNs function by inducing targeted double-strand breaks in DNA, which trigger cellular repair mechanisms capable of introducing specific mutations or replacing genes with high efficiency. Initially developed as a gene-targeting technology, ZFNs have evolved to find applications across various organisms and genetic contexts. Advancements in designing zinc-finger sets for new genomic targets, refining the design and selection processes remains an ongoing area of development. This technology's capability to facilitate targeted mutagenesis and gene replacement at high frequencies underscores its potential in advancing research and therapeutic applications. As methodologies continue to improve, ZFNs are expected to play a pivotal role in precision medicine, agriculture, and biotechnology, contributing to significant advancements and market expansion in genome editing technologies globally.
By Delivery Method Insights
The ex-vivo segment dominated the market with a share of 51.65% in 2023 the genome editing market, capturing a significant share. Ex vivo genome editing involves editing the genome of specific cells outside the body (in vitro), followed by the transplantation of these modified cells back into the patient to achieve therapeutic outcomes directly linked to the genetic modification. This approach offers distinct safety advantages, particularly in minimizing off-target gene editing risks, as the editing occurs in isolated cells under controlled laboratory conditions before reintroduction into the patient. Ex vivo genome editing is pivotal in advancing personalized medicine, as it allows for precise modifications tailored to individual genetic profiles. With ongoing advancements in technology and methodologies, ex vivo approaches are poised to drive further innovations in therapeutic applications, bolstering their prominence in the evolving landscape of genome editing delivery modes.
The in-vivo segment is projected to witness the fastest growth at a CAGR of 19.94% from 2024 to 2033 to advancements in technology that enable targeted gene modifications directly within the body. This approach eliminates the need for ex vivo manipulation of cells and offers potential benefits in terms of treatment efficiency and safety. Endonuclease-based strategies have shown promise in correcting diseases by targeting specific genes, driving ongoing research and clinical trials aimed at enhancing the therapeutic potential of in vivo genome editing across various genetic disorders. As these technologies continue to evolve and regulatory frameworks adapt, the in vivo segment is poised to play a pivotal role in shaping the future of genetic medicine.
By Application Insights
The genetic engineering segment held the largest market share in 2023 in genome editing, leveraging technologies that enable precise modifications to an organism's DNA. These tools facilitate the addition, removal, or alteration of genetic material at specific locations within the genome. One prominent approach is based on adapting bacterial immune defense systems, where RNA guides with specific sequences bind to targeted DNA sequences, akin to how bacteria use CRISPR arrays. This method enables researchers to edit DNA effectively and has widespread applications across various fields, driving innovation and growth in the genetic engineering market.
The clinical applications segment is expected to grow at a significant CAGR of 13.19% over the forecast period, particularly in germline genome editing, which involves modifying genetic material in germ cells and embryos. Unlike somatic genome editing, changes made in germline cells can be inherited by future generations. This approach holds promise for addressing genetic disorders and enhancing traits in offspring, with ongoing research exploring diverse targets and therapeutic purposes. As technologies advance, the application of genome editing in clinical settings continues to expand, driving forward new possibilities and advancements in genetic medicine.
By Mode Insights
The contract segment has emerged as the dominant force in the market, driven by genome editing technologies such as CRISPR/Cas. These advancements have significantly expanded the capabilities and efficiency of modifying genetic material in organisms. Genome editing is increasingly utilized to introduce agriculturally beneficial traits and genetic combinations in plants and animals. Contract services offer specialized expertise and resources to facilitate these genetic modifications, meeting the growing demand for tailored genetic solutions across agricultural sectors. This trend underscores the pivotal role of contract services in advancing genome editing applications for agricultural innovation and productivity enhancement.
The in-house segment is expected to grow at a CAGR of 13.4% from 2024 to 2033. This trend is driven by the adoption of in-house genetic counseling services, particularly in prenatal care settings. Studies have shown that integrating genetic counseling conducted by experienced professionals such as geneticist-obstetricians with expertise in prenatal ultrasound can notably enhance the detection rates of abnormal karyotypes. This approach provides healthcare facilities and institutions with greater control and customization over genetic counseling services, ensuring more effective prenatal care and diagnostic outcomes. As demand for personalized genetic counseling grows, the in-house model offers advantages in terms of efficiency, continuity of care, and enhanced patient outcomes, thereby fueling its anticipated expansion in the genetic counseling market.
By End-use Insights
The biotechnology and pharmaceutical companies segment accounted for the largest market share of 52% in 2023 in genome editing market in 2023. These companies have spearheaded the development of various genome editing techniques, with a notable focus on nucleases for precise genomic alterations. While multiple technologies have advanced to clinical trials, significant challenges persist in ensuring safe, scalable manufacturing and effective drug delivery. Biotech and pharmaceutical firms continue to innovate to overcome these hurdles, aiming to bring genome editing therapies to patients efficiently and affordably. Their leadership in this sector underscores their pivotal role in shaping the future of genetic medicine.
The academic and research institutions segment is expected to grow at the fastest CAGR of 19.22% over the forecast period in the genome editing market. These institutions play a crucial role in advancing genome editing technologies across various organisms and applications. CRISPR technology, for instance, enables researchers to create disease models in animals, study genetic causes, and develop cell models using human pluripotent stem cells. Genome editing is pivotal in modifying yeast cells for biofuel production and enhancing agricultural crop strains. The expanding use of genome editing tools in academic and research settings underscores their transformative potential in advancing scientific understanding and driving innovation across multiple fields.
Related report
Biotechnology Market : https://www.biospace.com/article/biotechnology-market-size-to-reach-usd-5-68-trillion-by-2033/
Cell and Gene Therapy Market : https://www.biospace.com/article/releases/u-s-cell-and-gene-therapy-clinical-trial-services-industry-is-rising-rapidly/
Cell And Gene Therapy Manufacturing Market : https://www.biospace.com/article/cell-and-gene-therapy-manufacturing-market-is-rising-rapidly/
Next Generation Sequencing Market : https://www.biospace.com/article/next-generation-sequencing-market-size-to-reach-usd-66-04-bn-by-2033/
Gene Therapy Market : https://www.biospace.com/article/releases/gene-therapy-market-size-poised-to-surge-usd-52-40-billion-by-2033/
Cancer Gene Therapy Market : https://www.biospace.com/article/releases/cancer-gene-therapy-industry-is-rising-rapidly-up-to-usd-18-11-bn-by-2033/
T-cell Therapy Market : https://www.biospace.com/article/releases/t-cell-therapy-market-size-share-and-analysis-report-2024-2033/
U.S. Gene Therapy Market : https://www.biospace.com/article/releases/u-s-gene-therapy-market-size-share-and-growth-report-2033/
U.S. Cell Therapy Market: https://www.biospace.com/article/u-s-cell-therapy-market-size-to-hit-usd-19-67-billion-by-2033/
Clinical Trials Market : https://www.biospace.com/article/releases/clinical-trials-market-size-to-increase-usd-153-59-billion-by-2033/
Cell Therapy Market : https://www.biospace.com/article/releases/cell-therapy-market-size-to-grow-at-22-67-percent-cagr-till-2033/
Gene Expression Market: https://www.biospace.com/article/gene-expression-market-size-to-reach-usd-37-35-billion-by-2033/
U.S. Gene Synthesis Market : https://www.biospace.com/article/releases/u-s-gene-synthesis-market-size-to-hit-usd-3-11-billion-by-2033/
U.S. Genome Editing Market : https://www.biospace.com/article/releases/u-s-genome-editing-market-size-to-hit-usd-16-49-billion-by-2033/
U.S. Consumer Genomics Market : https://www.biospace.com/article/releases/u-s-consumer-genomics-market-size-to-reach-usd-4-48-billion-by-2033/
U.S. Cell Separation Market : https://www.biospace.com/article/releases/u-s-cell-separation-market-is-rising-rapidly-up-to-usd-8-27-bn-by-2033/
U.S. Clinical Trials Market: https://www.biospace.com/article/releases/u-s-clinical-trials-market-size-industry-analysis-report-2033/
Antibiotics Market: https://www.biospace.com/article/releases/antibiotics-market-size-to-reach-usd-85-80-billion-by-2033/
Biosimilars Market: https://www.biospace.com/article/releases/biosimilars-market-size-poised-to-hit-usd-150-26-billion-by-2033/
U.S. Next Generation Sequencing Market: https://www.biospace.com/article/releases/u-s-next-generation-sequencing-market-size-to-worth-usd-25-71-bn-by-2033/
Recent Developments
- In August 2023, Precision BioSciences completed a strategic transaction with Imugene for Azer-Cel in cancer treatment
- In June 2024, Cryoport and Minaris Regenerative Medicine formed a strategic partnership to support the advancement of cell and gene therapies
- In May 2024, Editas Medicine, Inc. extended its collaboration with Bristol Myers Squibb to research, develop, and commercialize alpha-beta T cell medicines for cancer and autoimmune diseases
- In June 2024, Syngenta opened rights to genome-editing and breeding technologies to foster agricultural innovation
Immediate Delivery Available, Get Full Access@ https://www.novaoneadvisor.com/report/checkout/7129
Some of the prominent players in the Genome editing market include:
Key Genome Editing Companies:
The following are the leading companies in the genome editing market. These companies collectively hold the largest market share and dictate industry trends.
- Merck KGaA
- Cibus Inc.
- Recombinetics
- Sangamo Therapeutics
- Editas Medicine
- Precision BioSciences
- CRISPR Therapeutics
- Intellia Therapeutics, Inc.
- Caribou Biosciences, Inc
- Cellectis S.A.
- AstraZeneca
- Takara Bio Inc.
- Horizon Discovery Ltd. (Revvity, Inc.)
- Danaher Corporation
- Transposagen Biopharmaceuticals, Inc.
- Genscript Biotech Corp
- New England Biolabs
- OriGene Technologies, Inc.
- bluebird bio, Inc.
- Lonza
- Thermo Fisher Scientific, Inc
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global genome editing market.
By Technology
- (CRISPR)/Cas9
- TALENs/MegaTALs
- ZFN
- Meganuclease
- Others
By Delivery Method
- Ex-vivo
- In-vivo
By Application
- Genetic Engineering
- Cell line engineering
- Animal genetic engineering
- Plant genetic engineering
- Others
- Clinical Applications
- Diagnostics
- Therapy Development
By Mode
- Contract
- In-house
By End-use
- Biotechnology and pharmaceutical companies
- Academic and government research institutes
- Contract research organizations
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Procure Complete Report (220+ Pages PDF with Insights, Charts, Tables, and Figures) @
https://www.novaoneadvisor.com/report/checkout/7129
Call: USA: +1 650 460 3308 | IND: +91 87933 22019 |Europe: +44 2080772818
Email: sales@novaoneadvisor.com
Web: https://www.novaoneadvisor.com/
